SBLOF (Shin Nippon Biomedical Laboratories) Risk Assessment


SBLOF Shin Nippon Biomedical Laboratories Ltd SBLOF
74 GF Score
Price $9.16
GF Value $13.86
! 5 Warning Signs
View Full Analysis

What is Shin Nippon Biomedical Laboratories Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Shin Nippon Biomedical Laboratories is: No Data: Cannot be evaluated.

Shin Nippon Biomedical Laboratories  (OTCPK:SBLOF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Shin Nippon Biomedical Laboratories Risk Assessment Related Terms

SBLOF vs TMO, DHR, IDXX: Risk Assessment Comparison

For the Diagnostics & Research subindustry, Shin Nippon Biomedical Laboratories's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shin Nippon Biomedical Laboratories Risk Assessment vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Shin Nippon Biomedical Laboratories's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Shin Nippon Biomedical Laboratories's Risk Assessment falls into.


SBLOF
74GF Score
Shin Nippon Biomedical Laboratories Ltd SBLOF
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Shin Nippon Biomedical Laboratories (SBLOF) Overvalued in 2026?

Based on GuruFocus' analysis, Shin Nippon Biomedical Laboratories stock appears to be undervalued. The current stock price of $9.16 is trading 33.9% below its estimated GF Value™ of $13.86.

Key valuation signals for SBLOF:

  • Risk Assessment:
  • GF Value™: $13.86 vs. price of $9.16 (33.9% below fair value)
  • GF Score™: 74/100 with 5 warning signs

No single metric tells the full story. See the SBLOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shin Nippon Biomedical Laboratories Business Description

Other Exchanges 2395:JapanYB3:Germany
Address 8-1 Akashi-cho, Tokyo, JPN
Shin Nippon Biomedical Laboratories Ltd provides pre-clinical testing services in the pharmaceutical industry in Japan. The company provides a range of services such as pre-clinical and analysis studies, contracted clinical trials, SMO, CRO, translational research and cancer treatment.
74GF Score

Get the complete analysis for SBLOF

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.16
Price
$13.86
GF Value